TransCure bioServices, an Archamps, France-based one-stop-shop preclinical services company dedicated to in-vivo full human immune system mouse models, completed a €2.5m funding.
Financière Arbevel made the investment. In conjunction with the funding, Marc Le Bozec, Managing Director of Arbevel Life Sciences Crossover I Fund, will now join the Supervisory Board of TransCure bioServices.
The company intends to use the funds to:
– accelerate its international sales growth in Europe and the USA, as well as
– expand in vivo preclinical pharmacology services offers into new product lines.
Led by Patrick Nef, Chief Executive Officer and co-founder, and Stéphane Legastelois, Chairman, TransCure bioServices is a European CRO based in France offering pre-clinical in vivo pharmacology fee-for-services to international pharmaceutical, biotech and academic customers.
Uniquely designed full human immune system and hu-liver mouse models provide predictive power for drug profiling and smarter drug candidate selection for immuno-oncology, inflammation (IBD, SLE, MS, RA), auto-immune, infectious (HIV), liver diseases, and vaccines.